Genitourinary Syndrome of Menopause Clinical Trial
Official title:
Comparison Between Platelet-rich Plasma (PRP) and Hyaluronic Acid (HA) in the Treatment of Cancer-therapy Related Vulvovaginal Atrophy and Its Impact on Sexual Satisfaction
NCT number | NCT05782920 |
Other study ID # | 0201349 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 30, 2020 |
Est. completion date | March 31, 2021 |
Verified date | March 2023 |
Source | Alexandria University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to: 1. evaluate the efficacy of PRP injection and PRP injection mixed with non-cross-linked hyaluronic acid compared to the control group receiving standard therapy with topical non-cross-linked hyaluronic acid gel in the treatment of cancer therapy-induced or worsened vulvovaginal atrophy. 2. To evaluate the impact of vulvovaginal atrophy treatment on the sexual satisfaction of both partners. Patients will be divided randomly into 3 groups: Group 1: 15 female patients will receive vaginal PRP injections. Group 2: 15 female patients will receive vaginal PRP injections combined with non-cross-linked hyaluronic acid. Group 3: 15 female patients will receive topical non-cross-linked hyaluronic acid gel as a control group.
Status | Completed |
Enrollment | 45 |
Est. completion date | March 31, 2021 |
Est. primary completion date | March 31, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A to 70 Years |
Eligibility | Inclusion Criteria: - Patients have symptoms of VVA (vaginal dryness, burning, itching or dyspareunia) - Patients with vaginal health index < 15. - All patients have already finished cancer therapy or are on anti-estrogen treatment. - Married sexually active - Patients who are not receiving any VVA treatment for at least 30 days before starting therapy. Exclusion Criteria: - Active or recent history of vulvovaginal inflammation or infection - History of vulvar or vaginal cancer. - Suspicious lesion in the vulvovaginal area on the gynecological examination |
Country | Name | City | State |
---|---|---|---|
Egypt | Alexandria University | Alexandria |
Lead Sponsor | Collaborator |
---|---|
Alexandria University |
Egypt,
Hersant B, SidAhmed-Mezi M, Belkacemi Y, Darmon F, Bastuji-Garin S, Werkoff G, Bosc R, Niddam J, Hermeziu O, La Padula S, Meningaud JP. Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study. Menopause. 2018 Oct;25(10):1124-1130. doi: 10.1097/GME.0000000000001122. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Vulvovaginal atrophy vaginal dryness severity scores | scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms | before treatment | |
Primary | Vulvovaginal atrophy vaginal dryness severity scores | scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms | after 1 month | |
Primary | Vulvovaginal atrophy vaginal dryness severity scores | scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms | after 2 months | |
Primary | Vulvovaginal atrophy vaginal dryness severity scores | scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms | 3 months follow up | |
Primary | Vulvovaginal atrophy dyspareunia severity scores | scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms | before treatment | |
Primary | Vulvovaginal atrophy dyspareunia severity scores | scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms | after 1 month | |
Primary | Vulvovaginal atrophy dyspareunia severity scores | scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms | after 2 months | |
Primary | Vulvovaginal atrophy dyspareunia severity scores | scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms | 3 months follow up | |
Primary | Vaginal health index total score | scores range from 5-25 with lower scores signifying greater atrophy | before treatment | |
Primary | Vaginal health index total score | scores range from 5-25 with lower scores signifying greater atrophy | after 1 month | |
Primary | Vaginal health index total score | scores range from 5-25 with lower scores signifying greater atrophy | after 2 months | |
Primary | Vaginal health index total score | scores range from 5-25 with lower scores signifying greater atrophy | 3 months follow up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05812924 -
A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause
|
Phase 2 | |
Completed |
NCT04535323 -
Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer
|
Phase 1 | |
Completed |
NCT03331328 -
MonaLisa Touch Randomized Double-Blind Placebo Controlled Study
|
N/A | |
Recruiting |
NCT04746456 -
Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM
|
||
Withdrawn |
NCT04606550 -
MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study
|
N/A | |
Completed |
NCT04705883 -
Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors
|
Phase 4 | |
Recruiting |
NCT05953090 -
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
|
N/A | |
Active, not recruiting |
NCT04619485 -
Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy
|
N/A | |
Completed |
NCT04607798 -
Multi-polar RF and PEMF for Treatment of Vulvovaginal Atrophy
|
N/A | |
Recruiting |
NCT06124820 -
RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women With Recurrent Urinary Tract Infections
|
N/A | |
Completed |
NCT05561972 -
The Ultrasonographic Assessment of Efficacy of Injectable Hyaluronic Acid for Genitourinary Syndrome of Menopause
|
N/A | |
Recruiting |
NCT05571527 -
Comparison of Vaginal Hyaluronic Acid Treatment Over Autologous Platelet Rich Plasma Treatment for Genitourinary Syndrome of Menopause
|
N/A | |
Recruiting |
NCT04677491 -
Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders
|
Phase 4 | |
Not yet recruiting |
NCT06425978 -
Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit
|
Phase 4 | |
Recruiting |
NCT05672901 -
Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause
|
N/A | |
Recruiting |
NCT03782480 -
Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy
|
Phase 3 | |
Recruiting |
NCT06028009 -
PRP Injections for Genitourinary Syndrome of Menopause
|
N/A | |
Not yet recruiting |
NCT06007027 -
Vaginal CO2 Laser Therapy for Genitourinary Syndrome in Breast Cancer Survivors
|
N/A | |
Terminated |
NCT03857893 -
New Non-Hormonal Treatment by Radiofrequency for Vulvo-Vaginal Atrophy
|
N/A | |
Completed |
NCT05464654 -
Vaginal Biorevitalization With Polydeoxyribonucleotides for the Improvement of the Genitourinary Syndrome of Menopause
|
N/A |